Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

October 1, 2024

Study Completion Date

December 31, 2024

Conditions
GlioblastomaBrain Metastases
Interventions
DRUG

Losartan

This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.

Trial Locations (1)

0372

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Kyrre Eeg Emblem

OTHER